{"id":"pentoxifylline-trental-sr","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pentoxifylline works by inhibiting the enzyme phosphodiesterase, which breaks down cyclic AMP, a molecule that helps to relax blood vessels and improve blood flow. This leads to improved oxygen delivery to tissues and reduced inflammation.","oneSentence":"Pentoxifylline increases blood flow by improving red blood cell flexibility and reducing blood viscosity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:04.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Symptomatic relief of intermittent claudication"}]},"trialDetails":[{"nctId":"NCT05284656","phase":"PHASE3","title":"Effect of Folic Acid and/or Pentoxifylline on Patients With Chronic Kidney Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Al-Azhar University","startDate":"2022-01-08","conditions":"Chronic Kidney Diseases","enrollment":80},{"nctId":"NCT05284448","phase":"PHASE3","title":"Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2022-02-01","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":50},{"nctId":"NCT04977661","phase":"PHASE4","title":"Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2020-02-01","conditions":"Nonalcoholic Steatohepatitis (NASH)","enrollment":102}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"pentoxifylline (Trental SR®)","genericName":"pentoxifylline (Trental SR®)","companyName":"Al-Azhar University","companyId":"al-azhar-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pentoxifylline increases blood flow by improving red blood cell flexibility and reducing blood viscosity. Used for Symptomatic relief of intermittent claudication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}